Sivik Global Healthcare’s Repligen RGEN Stock Holding History

Sivik Global Healthcare’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,000	Closed	-$4.1M	–	44
2025 Q4	$4.1M	Sell	25,000 -2,500	-9%	-$392K	1.19%	30
2025 Q3	$3.68M	Sell	27,500 -2,500	-8%	-$304K	1.07%	38
2025 Q2	$3.73M	Buy	+30,000	New	+$3.82M	1.02%	35
2025 Q1	–	Sell	-10,000	Closed	-$1.44M	–	42
2024 Q4	$1.44M	Sell	10,000 -15,000	-60%	-$2.15M	0.76%	35
2024 Q3	$3.72M	Buy	25,000 +10,000	+67%	+$1.43M	1.58%	28
2024 Q2	$1.89M	Buy	+15,000	New	+$2.35M	0.68%	38
2021 Q1	–	Sell	-15,000	Closed	-$2.87M	–	58
2020 Q4	$2.87M	Buy	+15,000	New	+$2.73M	1.17%	35

Other funds holding RGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Sivik Global Healthcare's RGEN Position: Q1 2026 in Review

Sivik Global Healthcare sold out of Repligen (RGEN) in Q1 2026, closing a stake of 25,000 shares — an estimated $4.1M sold.

Sivik Global Healthcare first reported a position in RGEN in Q4 2020 and held it in 7 quarters. The position peaked at $4.1M in Q4 2025. 442 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

Sivik Global Healthcare reported no remaining Repligen position as of Q1 2026 after selling out during the quarter.
Sivik Global Healthcare sold 25,000 Repligen shares in Q1 2026, an estimated $4.1M.
Sivik Global Healthcare first reported a position in Repligen in Q4 2020 and held it in 7 quarters.
Sivik Global Healthcare's Repligen position peaked at $4.1M in Q4 2025.
442 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on Sivik Global Healthcare's 13F filing for Q1 2026, filed 15 Apr 2026.